Chris H. Takimoto - Concepedia

Author

Chris H. Takimoto

The University of Texas Health Science Center at San Antonio

Also Known As

C H Takimoto, C Takimoto, C. H. M. Takimoto, C. H. Takimoto, C. TAKIMOTO, C. Takimoto, C.H. Takimoto, CHRIS H. TAKIMOTO, Chris H Takimoto, Chris H. Takimoto

321

Publications

13K

Citations

H-Index

121

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio National Cancer Institute Stanford University Menlo School City of Hope

About

Chris H. Takimoto is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	67	3.6K
2	Health Sciences	7	7	659
3	Natural Sciences	5	5	651
4	Engineering	2	2	59
5	Allergy	1	1	11

Chris H. Takimoto

123

Publications

11.5K

Citations

H-Index

Page 1

	Year	Citations
Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol, Journal of Clinical Oncology	2007	1.1K
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, New England Journal of Medicine	2018	1.1K
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Journal of Clinical Oncology	2001	997
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas Robert G. Maki, David R. D’Adamo, Mary Louise Keohan, Journal of Clinical Oncology Surgical OncologySarcoma SubtypeMalignant DiseaseMedicineDaily Oral Sorafenib	2009	569
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik, Journal of Clinical Oncology	2019	564
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers, Investigational New Drugs Cnto 888MedicineHuman Monoclonal AntibodyImmunologyImmune Checkpoint Inhibitor	2012	389
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Mariafiorella Brangi, Thomas Litman, Marco Ciotti, PubMed Intrinsic Drug ResistanceCellular PharmacologyCancer BiologyRedox BiologyCellular Physiology	1999	261
Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors Jean L. Grem, Geraldine Morrison, Xiao-Du Guo, Journal of Clinical Oncology	2005	244
An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors María L. Amador, Darin Oppenheimer, Sofía Perea, Cancer Research	2004	242
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin Anthony W. Tolcher, Alain C. Mita, Lionel D. Lewis, Journal of Clinical Oncology	2008	239

Page 1